NO2872646T3 - - Google Patents
Info
- Publication number
- NO2872646T3 NO2872646T3 NO13735334A NO13735334A NO2872646T3 NO 2872646 T3 NO2872646 T3 NO 2872646T3 NO 13735334 A NO13735334 A NO 13735334A NO 13735334 A NO13735334 A NO 13735334A NO 2872646 T3 NO2872646 T3 NO 2872646T3
- Authority
- NO
- Norway
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
- C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
- C12Q2537/143—Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12305836 | 2012-07-12 | ||
PCT/EP2013/064808 WO2014009535A2 (fr) | 2012-07-12 | 2013-07-12 | Procédés de prédiction de la durée de survie et de la réponse au traitement d'un patient souffrant d'un cancer solide avec une signature d'au moins 7 gènes |
EP13735334.8A EP2872646B1 (fr) | 2012-07-12 | 2013-07-12 | Procédés permettant de prédire le temps de survie et la réactivité à un traitement chez un patient souffrant d'un cancer solide avec une signature de 21 gènes |
Publications (1)
Publication Number | Publication Date |
---|---|
NO2872646T3 true NO2872646T3 (fr) | 2018-01-27 |
Family
ID=48782367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO13735334A NO2872646T3 (fr) | 2012-07-12 | 2013-07-12 |
Country Status (8)
Country | Link |
---|---|
US (2) | US11242564B2 (fr) |
EP (1) | EP2872646B1 (fr) |
JP (3) | JP6923291B2 (fr) |
DK (1) | DK2872646T3 (fr) |
ES (1) | ES2648176T3 (fr) |
NO (1) | NO2872646T3 (fr) |
PL (1) | PL2872646T3 (fr) |
WO (1) | WO2014009535A2 (fr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2872646T3 (en) * | 2012-07-12 | 2017-12-04 | Université Paris Descartes | PROCEDURES FOR PREDICTING SURVIVAL TIME AND TREATMENT RESPONSE OF A PATIENT, SUFFERING A FAST CANCER WITH A SIGNATURE OF AT LEAST 7 GENES |
WO2015077717A1 (fr) | 2013-11-25 | 2015-05-28 | The Broad Institute Inc. | Compositions et méthodes pour diagnostiquer, évaluer et traiter un cancer au moyen d'un état de méthylation d'adn |
WO2015085147A1 (fr) | 2013-12-05 | 2015-06-11 | The Broad Institute Inc. | Typage de gènes polymorphes et détection de changements somatiques à l'aide de données de séquençage |
EP3084003A4 (fr) * | 2013-12-17 | 2017-07-19 | Merck Sharp & Dohme Corp. | Biomarqueurs de signature du gène ifn-gamma de la réponse tumorale à des antagonistes de pd-1 |
US20160312295A1 (en) * | 2013-12-17 | 2016-10-27 | Merck Sharp & Dohme Corp. | Gene signature biomarkers of tumor response to pd-1 antagonists |
KR20160101073A (ko) | 2013-12-20 | 2016-08-24 | 더 브로드 인스티튜트, 인코퍼레이티드 | 신생항원 백신과의 병용 요법 |
CN107148274A (zh) * | 2014-08-19 | 2017-09-08 | 国立大学法人冈山大学 | 增强免疫细胞功能的方法和评估免疫细胞多功能性的方法 |
WO2016049276A1 (fr) * | 2014-09-25 | 2016-03-31 | Moffitt Genetics Corporation | Biomarqueurs de tumeurs pronostiques |
WO2016073378A1 (fr) | 2014-11-03 | 2016-05-12 | Genentech, Inc. | Tests de détection de sous-ensembles immunitaires de cellules t et leurs procédés d'utilisation |
MX2017005751A (es) * | 2014-11-03 | 2018-04-10 | Genentech Inc | Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40. |
CA2968406A1 (fr) | 2014-12-09 | 2016-06-16 | Mark D. Ayers | Systeme et procedes pour deriver des marqueurs biologiques de signature genique de reponse a des antagonistes de pd-1 |
EP3234193B1 (fr) | 2014-12-19 | 2020-07-15 | Massachusetts Institute of Technology | Biomarqueurs moléculaires pour l'immunothérapie d'un cancer |
US10993997B2 (en) | 2014-12-19 | 2021-05-04 | The Broad Institute, Inc. | Methods for profiling the t cell repertoire |
BR112017020054A2 (pt) | 2015-03-23 | 2018-06-05 | Jounce Therapeutics Inc | anticorpos para icos |
EP3073268A1 (fr) | 2015-03-27 | 2016-09-28 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Panel de biomarqueurs pour le diagnostic du cancer |
EP3839510A3 (fr) * | 2015-04-17 | 2021-08-25 | Merck Sharp & Dohme Corp. | Biomarqueurs sanguins de la sensibilité d'une tumeur à des antagonistes de pd-1 |
CN116196401A (zh) | 2015-05-20 | 2023-06-02 | 博德研究所 | 共有的新抗原 |
JP6831112B2 (ja) * | 2015-10-15 | 2021-02-17 | 国立大学法人京都大学 | Pd−1経路阻害薬の著効例を予測するためのバイオマーカー |
EP3365372A1 (fr) * | 2015-10-22 | 2018-08-29 | Jounce Therapeutics, Inc. | Signatures géniques pour déterminer l'expression d'icos |
WO2017096458A1 (fr) * | 2015-12-07 | 2017-06-15 | Ontario Institute For Cancer Research (Oicr) | Signature génique immunitaire prédictive des bienfaits de l'anthracycline |
CN109195634A (zh) * | 2016-04-15 | 2019-01-11 | 延龄草疗法有限公司 | Cd47阻断治疗中的巨噬细胞刺激 |
CN115198018A (zh) * | 2016-05-09 | 2022-10-18 | 法国国家卫生及研究医学协会 | 患有实体癌症的患者的分类方法 |
EP3487522A4 (fr) | 2016-07-19 | 2020-04-01 | Teva Pharmaceuticals Australia Pty Ltd | Polythérapie anti-cd47 |
WO2018045346A1 (fr) * | 2016-09-01 | 2018-03-08 | Autotelic Llc | Méthodes de traitement du cancer et de détermination de l'efficacité d'un traitement |
EP3574116A1 (fr) | 2017-01-24 | 2019-12-04 | The Broad Institute, Inc. | Compositions et procédés de détection d'un variant mutant d'un polynucléotide |
WO2018232142A1 (fr) * | 2017-06-14 | 2018-12-20 | Icahn School Of Medicine At Mount Sinai | Procédés pour la détection et le traitement de classes de carcinome hépatocellulaire sensible à une immunothérapie |
CN110770849A (zh) * | 2017-06-16 | 2020-02-07 | 南托米克斯有限责任公司 | Praegnant转移性乳腺癌群组中的不良结果的预后指标 |
SG11202112712RA (en) | 2019-06-03 | 2021-12-30 | Inst Nat Sante Rech Med | Methods for modulating a treatment regimen |
MX2022004501A (es) | 2019-11-07 | 2022-05-06 | Oncxerna Therapeutics Inc | Clasificacion de microambientes tumorales. |
MX2022011811A (es) | 2020-04-01 | 2022-10-07 | Avalo Therapeutics Inc | Metodos y tratamiento con exceso de light libre. |
GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
AU2021293006A1 (en) * | 2020-06-18 | 2023-02-02 | Macrogenics, Inc. | Use of bispecific CD123 x CD3 diabodies for the treatment of hematologic malignancies |
CN115843335A (zh) | 2020-06-30 | 2023-03-24 | 国家医疗保健研究所 | 用于预测患有实体癌的患者在术前辅助治疗和根治性手术后复发和/或死亡风险的方法 |
CN115997123A (zh) | 2020-06-30 | 2023-04-21 | 国家医疗保健研究所 | 用于预测实体癌患者在术前辅助治疗后复发和/或死亡风险的方法 |
WO2023175366A1 (fr) | 2022-03-17 | 2023-09-21 | Veracyte | Méthodes de prédiction de la réponse à un traitement immunothérapeutique chez un patient atteint d'un cancer |
Family Cites Families (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4888278A (en) | 1985-10-22 | 1989-12-19 | University Of Massachusetts Medical Center | In-situ hybridization to detect nucleic acid sequences in morphologically intact cells |
US5447841A (en) | 1986-01-16 | 1995-09-05 | The Regents Of The Univ. Of California | Methods for chromosome-specific staining |
US6280929B1 (en) | 1986-01-16 | 2001-08-28 | The Regents Of The University Of California | Method of detecting genetic translocations identified with chromosomal abnormalities |
US4774339A (en) | 1987-08-10 | 1988-09-27 | Molecular Probes, Inc. | Chemically reactive dipyrrometheneboron difluoride dyes |
US5132432A (en) | 1989-09-22 | 1992-07-21 | Molecular Probes, Inc. | Chemically reactive pyrenyloxy sulfonic acid dyes |
US5274113A (en) | 1991-11-01 | 1993-12-28 | Molecular Probes, Inc. | Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates |
US5433896A (en) | 1994-05-20 | 1995-07-18 | Molecular Probes, Inc. | Dibenzopyrrometheneboron difluoride dyes |
US5248782A (en) | 1990-12-18 | 1993-09-28 | Molecular Probes, Inc. | Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes |
US5338854A (en) | 1991-02-13 | 1994-08-16 | Molecular Probes, Inc. | Fluorescent fatty acids derived from dipyrrometheneboron difluoride dyes |
US5427932A (en) | 1991-04-09 | 1995-06-27 | Reagents Of The University Of California | Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using |
US5187288A (en) | 1991-05-22 | 1993-02-16 | Molecular Probes, Inc. | Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis |
US5505928A (en) | 1991-11-22 | 1996-04-09 | The Regents Of University Of California | Preparation of III-V semiconductor nanocrystals |
US5262357A (en) | 1991-11-22 | 1993-11-16 | The Regents Of The University Of California | Low temperature thin films formed from nanocrystal precursors |
US6048616A (en) | 1993-04-21 | 2000-04-11 | Philips Electronics N.A. Corp. | Encapsulated quantum sized doped semiconductor particles and method of manufacturing same |
US5472842A (en) | 1993-10-06 | 1995-12-05 | The Regents Of The University Of California | Detection of amplified or deleted chromosomal regions |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US5571018A (en) | 1994-11-23 | 1996-11-05 | Motorola, Inc. | Arrangement for simulating indirect fire in combat training |
US5690807A (en) | 1995-08-03 | 1997-11-25 | Massachusetts Institute Of Technology | Method for producing semiconductor particles |
US5800996A (en) | 1996-05-03 | 1998-09-01 | The Perkin Elmer Corporation | Energy transfer dyes with enchanced fluorescence |
US5830912A (en) | 1996-11-15 | 1998-11-03 | Molecular Probes, Inc. | Derivatives of 6,8-difluoro-7-hydroxycoumarin |
US5696157A (en) | 1996-11-15 | 1997-12-09 | Molecular Probes, Inc. | Sulfonated derivatives of 7-aminocoumarin |
US5866366A (en) | 1997-07-01 | 1999-02-02 | Smithkline Beecham Corporation | gidB |
US6130101A (en) | 1997-09-23 | 2000-10-10 | Molecular Probes, Inc. | Sulfonated xanthene derivatives |
US6322901B1 (en) | 1997-11-13 | 2001-11-27 | Massachusetts Institute Of Technology | Highly luminescent color-selective nano-crystalline materials |
US5990479A (en) | 1997-11-25 | 1999-11-23 | Regents Of The University Of California | Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes |
US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
US6617583B1 (en) | 1998-09-18 | 2003-09-09 | Massachusetts Institute Of Technology | Inventory control |
US6114038A (en) | 1998-11-10 | 2000-09-05 | Biocrystal Ltd. | Functionalized nanocrystals and their use in detection systems |
US6855202B2 (en) | 2001-11-30 | 2005-02-15 | The Regents Of The University Of California | Shaped nanocrystal particles and methods for making the same |
EP1179185B1 (fr) | 1999-05-07 | 2009-08-12 | Life Technologies Corporation | Procede de detection d'une substance a analyser au moyen de nanocristaux semiconducteurs |
US6306736B1 (en) | 2000-02-04 | 2001-10-23 | The Regents Of The University Of California | Process for forming shaped group III-V semiconductor nanocrystals, and product formed using process |
US6225198B1 (en) | 2000-02-04 | 2001-05-01 | The Regents Of The University Of California | Process for forming shaped group II-VI semiconductor nanocrystals, and product formed using process |
WO2001071043A1 (fr) | 2000-03-22 | 2001-09-27 | Quantum Dot Corporation | Dosage d'hybridation de sonde a boucle pour analyser des polynucleotides |
US6689338B2 (en) | 2000-06-01 | 2004-02-10 | The Board Of Regents For Oklahoma State University | Bioconjugates of nanoparticles as radiopharmaceuticals |
US6716979B2 (en) | 2000-08-04 | 2004-04-06 | Molecular Probes, Inc. | Derivatives of 1,2-dihydro-7-hydroxyquinolines containing fused rings |
US6942970B2 (en) | 2000-09-14 | 2005-09-13 | Zymed Laboratories, Inc. | Identifying subjects suitable for topoisomerase II inhibitor treatment |
US6649138B2 (en) | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
US20020083888A1 (en) | 2000-12-28 | 2002-07-04 | Zehnder Donald A. | Flow synthesis of quantum dot nanocrystals |
US6670113B2 (en) | 2001-03-30 | 2003-12-30 | Nanoprobes | Enzymatic deposition and alteration of metals |
US6709929B2 (en) | 2001-06-25 | 2004-03-23 | North Carolina State University | Methods of forming nano-scale electronic and optoelectronic devices using non-photolithographically defined nano-channel templates |
WO2003092043A2 (fr) | 2001-07-20 | 2003-11-06 | Quantum Dot Corporation | Nanoparticules luminescentes et techniques de preparation |
AU2003284880A1 (en) * | 2002-10-24 | 2004-05-13 | Duke University | Evaluation of breast cancer states and outcomes using gene expression profiles |
EP2481814A3 (fr) * | 2003-06-09 | 2012-10-10 | The Regents of the University of Michigan | Compositions et procédés de diagnostic et de traitement des cancers |
WO2005003777A2 (fr) | 2003-06-24 | 2005-01-13 | Ventana Medical Systems, Inc. | Depot de metal catalyse par une enzyme pour la detection in situ amelioree d'epitopes immunohistochimiques et de sequences d'acides nucleiques |
US7642064B2 (en) | 2003-06-24 | 2010-01-05 | Ventana Medical Systems, Inc. | Enzyme-catalyzed metal deposition for the enhanced detection of analytes of interest |
AU2006239154A1 (en) | 2005-04-28 | 2006-11-02 | Ventana Medical Systems, Inc | Nanoparticle conjugates |
EP3144675A1 (fr) | 2005-04-28 | 2017-03-22 | Ventana Medical Systems, Inc. | Enzymes conjuguées à des anticorps via un lieur peg hétérobifontionnel |
KR101498834B1 (ko) * | 2005-05-09 | 2015-03-05 | 오노 야꾸힝 고교 가부시키가이샤 | 예정 사멸 인자 1(pd-1)에 대한 인간 모노클로날 항체, 및 항-pd-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법 |
EP1777523A1 (fr) * | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthode pour pronostiquer la progression d'un cancer et les résultats du patient et les moyens pour performer la méthode |
CN104090095B (zh) | 2005-11-23 | 2016-06-01 | 文塔纳医疗系统公司 | 分子缀合物 |
CA2631236C (fr) | 2005-12-01 | 2019-10-29 | Medical Prognosis Institute | Methodes et appareils pour identifier des biomarqueurs de reponse a un traitement et leur utilisation pour predire l'efficacite d'un traitement |
EP2258874B1 (fr) * | 2006-06-02 | 2015-03-18 | GlaxoSmithKline Biologicals S.A. | Procédé d'identification si un patient est réactif ou non à l'immunothérapie |
CN101970664B (zh) * | 2008-01-16 | 2013-08-21 | 林希龙 | 使用可诱导的重组核糖核酸因子生成不含肿瘤的类胚胎干细胞的多能性细胞 |
WO2010144192A1 (fr) * | 2009-05-05 | 2010-12-16 | Children's Medical Center Corporation | Indicateurs de pronostic pour tumeurs solides humaines |
JP2012533322A (ja) * | 2009-07-20 | 2012-12-27 | ジェネンテック, インコーポレイテッド | クローン病のための遺伝子発現マーカー |
US20120245235A1 (en) * | 2009-12-01 | 2012-09-27 | Compenda Bioscience, Inc | Classification of cancers |
US9404926B2 (en) * | 2010-01-29 | 2016-08-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Immune gene signatures in cancer |
DK2872646T3 (en) * | 2012-07-12 | 2017-12-04 | Université Paris Descartes | PROCEDURES FOR PREDICTING SURVIVAL TIME AND TREATMENT RESPONSE OF A PATIENT, SUFFERING A FAST CANCER WITH A SIGNATURE OF AT LEAST 7 GENES |
-
2013
- 2013-07-12 DK DK13735334.8T patent/DK2872646T3/en active
- 2013-07-12 PL PL13735334T patent/PL2872646T3/pl unknown
- 2013-07-12 US US14/413,856 patent/US11242564B2/en active Active
- 2013-07-12 NO NO13735334A patent/NO2872646T3/no unknown
- 2013-07-12 WO PCT/EP2013/064808 patent/WO2014009535A2/fr active Application Filing
- 2013-07-12 JP JP2015521016A patent/JP6923291B2/ja active Active
- 2013-07-12 EP EP13735334.8A patent/EP2872646B1/fr active Active
- 2013-07-12 ES ES13735334.8T patent/ES2648176T3/es active Active
-
2019
- 2019-05-28 JP JP2019099354A patent/JP6936277B2/ja active Active
-
2021
- 2021-07-07 JP JP2021112781A patent/JP7378443B2/ja active Active
- 2021-12-27 US US17/562,111 patent/US20220259665A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2015528698A (ja) | 2015-10-01 |
WO2014009535A3 (fr) | 2014-04-17 |
WO2014009535A2 (fr) | 2014-01-16 |
US20150203919A1 (en) | 2015-07-23 |
JP6936277B2 (ja) | 2021-09-15 |
DK2872646T3 (en) | 2017-12-04 |
JP7378443B2 (ja) | 2023-11-13 |
US11242564B2 (en) | 2022-02-08 |
ES2648176T3 (es) | 2017-12-28 |
PL2872646T3 (pl) | 2018-03-30 |
JP6923291B2 (ja) | 2021-08-18 |
JP2019162138A (ja) | 2019-09-26 |
EP2872646B1 (fr) | 2017-08-30 |
US20220259665A1 (en) | 2022-08-18 |
JP2021166539A (ja) | 2021-10-21 |
EP2872646A2 (fr) | 2015-05-20 |